Publisher
Springer Berlin Heidelberg
Reference14 articles.
1. Baier JE (1995) Bisphosphonates - cellular mode of action. Influence on mediators within the immune system. Tumordiagn Ther 16:4–11.
2. Bataille R, Capparad D, Klein B (1992) Mechanisms of bone lesion in multiple myeloma. Hematol Oncol Clin North Am 6:285–295.
3. Berenson JR Lichtenstein A Porter L etal (1996) Efficacy in reducing skeletal events in patients with advanced muliple myeloma. N Engl J Med 334:488–493.
4. Diel IJ, SolomayerEF, Goerner R, Gollan C, Wallwiener D, Bastea G (1997) Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases. Am Soc Clin Oncol 16: abstract 461.
5. Hortobagyi GN, Theriaut RL, Porter L, etal for the Protocol 19 Aredia Breast Cancer Study Group (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1791.